pharmaceutical-innovation
3 cases — ← All topics
| Case | Title | Lower Court | Docketed | Status | Flags | Tags | Question Presented |
|---|---|---|---|---|---|---|---|
| 24-1132 | Purdue Pharma L.P., et al. v. Accord Healthcare, Inc. | Federal Circuit | 2025-05-02 | Denied | federal-circuit non-obviousness obviousness patent-law pharmaceutical-innovation secondary-considerations | Whether the objective indicia of non-obviousness should be analyzed flexibly to combat hindsight bias or subject to the Federal Circuit's rigid rules … | |
| 20-380 | Idenix Pharmaceuticals LLC, et al. v. Gilead Sciences, Inc. | Federal Circuit | 2020-09-24 | Denied | Amici (3)Response RequestedResponse WaivedRelisted (2) | 35-usc-112a enablement genus-claim genus-claims patent patent-law pharmaceutical-innovation pharmaceuticals statutory-interpretation written-description | Whether the Federal Circuit's genus-claim-specific enablement rule and separate 'possession' requirement are consistent with 35 U.S.C. § 112(a) |
| 18-1280 | Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., et al. | Federal Circuit | 2019-04-08 | Denied | Amici (5) | blocking-patent-doctrine blocking-patents burden-of-proof graham-v-john-deere nonobviousness objective-indicia obviousness patent patent-law patent-obviousness pharmaceutical-innovation prior-art | Whether objective indicia of nonobviousness may be partially or entirely discounted where the development of the invention was allegedly 'blocked' by … |